Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole.

ABSTRACT:

Background

If left untreated, vitreomacular traction (VMT) will infrequently improve through spontaneous resolution of vitreomacular adhesion (VMA), and patients remain at risk of further deterioration in vision. The mainstay of treatment for VMT is vitrectomy, an invasive procedure that carries the risk of rare but serious complications and further vision loss. As such, a 'watch and wait' approach is often adopted before this surgical intervention is performed. Ocriplasmin (microplasmin) is a potential alternative treatment for patients with symptomatic VMT that may remove the requirement for vitrectomy.

Objective

The purpose of this study was to evaluate the cost-effectiveness of ocriplasmin for the treatment of VMT in comparison to standard of care.

Study design

A

SUBMITTER: Bennison C 

PROVIDER: S-EPMC4920942 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature